Prospective Evaluation of Intravitreal Triamcinolone Acetonide Injection in Macular Edema Associated with Retinal Vascular Disorders

Abstract

Purpose

To evaluate the effect of intravitreal triamcinolone acetonide on visual acuity and macular thickness using optical coherence tomography (OCT) in macular edema associated with various retinal vascular disorders.

Methods

This prospective nonrandomized clinical interventional study included 81 eyes (76 patients) comprised of Group I, 57 eyes (51 patients) with diabetic macular edema; Group II, 10 eyes (10 patients) with branch retinal vein occlusion; and Group III, 13 eyes (13 patients) with central retinal vein occlusion. All eyes received an intravitreal injection of 4 mg triamcinolone acetonide (with the solvent) in the operation theater under sterile conditions.

Results

Mean preinjection central macular thickness was 531.84±132 μm in Group I, 458.4±149 μm in Group II, and 750.81±148 μm in Group III. All groups showed a statistically significant decrease in mean central macular thickness at 1 month (300.7±119 μM in Group I, 218.2±99 μm in Group II, and 210.5 ±56 μm in Group III) and 3 months (253.19±109 μm in Group I, 187±47 μm in Group II, and 182±50 μm in Group III) after injection (p<0.05). Mean follow-up was 22±2.4 weeks. Mean visual acuity increased in all three groups (preoperative visual acuity in Group I, 1.2±0.4 logMAR units; Group II, 1.24±0.5 logMAR units; Group III, 1.1 ±0.4 logMAR units; 1 month postinjection in Group I, 0.88±0.3 logMAR units; Group II, 0.67±0.3 logMAR units; Group III, 0.86±0.4 logMAR units; 3 months postinjection in Group I, 0.84±0.4 logMAR units; Group II, 0.59±0.3 logMAR units; Group III, 0.82±0.5 logMAR units) (p<0.05). Forty-one eyes completed 6 months and 20 eyes completed 9 months follow-up. Twelve of 20 (41%) eyes in Group I, 2/6 (33%) eyes in Group II, 3/6 (50%) eyes in Group III, and 8/15 (53%) eyes in Group I, 1/3 (33%) eyes in Group II, and 2/2 (100%) eyes in Group III developed recurrence of macular edema with worsening of visual acuity at 6 and 9 months, respectively. Thirty-three (40.7%) eyes developed IOP elevation (at least one reading > 24 mmHg). One eye developed infective endophthalmitis.

Conclusions

Intravitreal injection of triamcinolone acetonide may be considered as an effective treatment for reducing macular thickening due to diffuse diabetic macular edema, venous occlusion associated macular edema, and may result in increase in visual acuity at least in the short term. Further follow-up and analysis is required to demonstrate its long-term efficacy.

Keywords

Intravitreal triamcinolone acetonide Diabetic macular edema Central retinal vein occlusion Branch retinal vein occlusion

Get full access to this article

View all access options for this article.

References

Klein

, Klein

B.E.

, Moss

S.E.

Visual impairment in diabetes. Ophthalmology 1984; 91: 1–9.

Natural history and clinical management of central vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol 1997; 115: 486–91.

Glacet-Bernard

, Coscas

, Ghabenel

Prognostic factors for branch vein occlusion. Prospective study of 175 cases. Ophthalmology 1996; 103: 551–60.

Early Treatment Diabetic Retinopathy Study Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report no. 1. Arch Ophthalmol 1985; 103: 1796–806.

The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984; 98: 271–82.

The Central Vein Occlusion Study Group. Evaluation of grid laser photocoagulation for macular edema in central vein occlusion. Ophthalmology 1995; 102: 1425–33.

Lee

C.M.

, Oik

R.J.

Modified grid laser photocoagulation for diffuse diabetic macular edema. Long term visual results. Ophthalmology 1991; 98: 1594–602.

Shilling

J.S.

, Jonas

C.A.

Retinal branch vein occlusion. A study of argon laser photocoagulation in treatment of macular edema. Br J Ophthalmol 1984; 68: 196–8.

Lewis

, Abram

G.W.

, Blumenkranz

M.S.

, Camp

R.V.

Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992; 99: 753–9.

10.

Jonas

J.B.

, Sofker

Intravitreal injection of crystalline cortisone as an adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001; 132: 425–7.

11.

Jonas

J.B.

, Degenring

R.F.

, Kampperter

B.A.

, Kreissig

, Akkoyou

Duration of the effect of intravitreal triamcinolone as a treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004; 138: 158–60.

12.

Massin

, Andren

, Hauchine

Intravitreal triamcinolone for diffuse diabetic macular edema. Preliminary results of a prospective controlled trial. Ophthalmology. 2004; 111: 218–25.

13.

Jonas

J.B.

, Kreissig

, Sifker

, Degenrinf

R.F.

Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003; 121: 57–61.

14.

Martidis

, Duker

J.S.

, Greenberg

P.B.

Intravitreal triamcinolone for refractory macular edema. Ophthalmology 2003; 109: 920–7.

15.

Karacorlu

, Ozdemier , Karacolu

Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion in young patients. Retina 2004; 24: 324–7.

16.

Park

, Jaffe

G.J.

, Fekrat

Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 2003; 136: 419–25.

17.

Chen

S.D.

, Lochhead

, Patel

C.K.

, Futh

Intravitreal triamcinolone acetonide for ischemic macular edema caused by branch retinal vein occlusion. Br J Ophthalmol 2004; 88: 154–5.

18.

Degenring

R.F.

, Kamppeter

, Kreissig

, Jonas

J.B.

Morphological and structural changes after intravitreal triamcinolone acetonide for retinal vein occlusion. Acta Ophthalmol Scand 2003; 81: 548–50.

19.

Green berg

P.B.

, Martidis

, Rogers

A.H.

, Duker

J.B.

, Reichel

Intravitreal triamcinolone acetonide for macular edema due to central retinal vein occlusion. Br J Ophthalmol 2002; 86: 247–8.

20.

McCuen

2nd , Bessler

, Tano

, Chandler

, Machemer

The lack of toxicity of intravitreal triamcinolone acetonide. Am J Ophthalmol 1981; 91: 785–8.

21.

Bakeri

S.J.

, Beer

P.M.

Effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003; 34: 386–90.

22.

Gilles

M.C.

, Simpson

J.M.

, Billson

F.A.

Safety of intravitreal injection of triamcinolone. Results of randomized clinical trial. Arch Ophthalmol 2004; 122: 336–40.

23.

Danis

R.P.

, Cuilla

T.A.

, Pratt

L.M.

, Antiker

Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20: 244–50.

24.

Canway

M.D.

, Canakis

, Livir

, Peyman

G.A.

Intravitreal triamcinolone acetonide for refractory chronic Pseudophakic cystoid macula edema. J Cataract Refract Surg 2003; 29: 27–33.

25.

Young

, Larkin

, Branley

, Lightmen

Safety and efficacy of intravitreal triamcinolone acetonide for cystoid macular edema in uveitis. Clin Exp Ophthalmol 2001; 129: 2–6.

26.

Saraina

V.S.

, Sallum

J.M.

, Farah

M.E.

Treatment of cystoid macular edema related to retinitis pigmentosa with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging 2003; 34: 398–400.

27.

Jonas

J.B.

, Akkoyn

, Kamppeter

, Kreissig

, Degenring

R.F.

Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 2005; 19: 65–71.

28.

Beer

P.M.

Intraocular concentration and pharmacokinetics of triamcinolone acetonide after single intravitreal injection. Ophthalmology 2003; 110: 681–6.

29.

Wingata

R.J.

, Beaurmont

P.E.

Intravitreal triamcinolone and elevated intraocular pressure. Aust NZ J Ophthalmol 1999; 27: 431–2.

30.

Jonas

J.B.

, Krissig

, Degenring

R.F.

Intraocular pressure after injection of triamcinolone. Br J Ophthalmol 2003; 57: 24–7.

31.

Sutter

F.K.

, Gilles

M.C.

Pseudoendophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003; 87: 972–4.

32.

Moshfeght

D.M.

, Kauser

P.K.

, Scott

I.U.

Acute endophthalmitis following intravitreal triamcinolone. Am J Ophthalmol 2003; 136: 791–6.

33.

Chen

S.D.

, Mohammed

, Bowling

, Patel

C.K.

Vitreous wick syndrome: a potential cause of endophthalmitis after intravitreal injection of triamcinolone through pars plana. Am J Ophthalmol 2004; 137: 1159–60.

34.

Venkatesh

, Verma

, Tewari

H.K.

Posterior vitreous wick syndrome: a potential cause following vitreoretinal surgery. Med Hypoth 2002; 58: 513–5.